Tma master 01

Manufactured by 3DHISTECH

Sourced in Hungary

The TMA master-01 is a laboratory equipment designed for tissue microarray (TMA) construction. It provides a platform for the efficient creation of TMA blocks, which are used in histological analyses and research. The core function of the TMA master-01 is to facilitate the precise extraction and assembly of tissue cores from donor tissue samples into a recipient paraffin block.

Automatically generated - may contain errors

Lab products found in correlation

Mum1p, by Agilent Technologies (1 mentions) Ish iview blue detection kit, by Roche (1 mentions) Ber h2, by Agilent Technologies (1 mentions)

2 protocols using tma master 01

Immunohistochemical Profiling of PTLD Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

Primary diagnostic formalin fixed paraffin-embedded tissue samples containing representative PTLD were available from 52 patients; samples of these were included in a tissue microarray (TMA). Briefly, three 1-mm diameter tissue cores were identified in tumor areas, punched out and re-embedded in recipient blocks using a TMA master-01 (3DHISTECH Ltd., Budapest, Hungary).
Immunohistochemical stains were performed on 4 μm formalin fixed paraffin-embedded tissue sections according to standard antibody-specific protocols, optimized in house for use with the Ventana Benchmark automated staining system (Ventana Medical Systems, Tucson, AZ). For review of the classification of the tumors according to WHO 2008 criteria, a panel of markers was applied consisting of CD3 (polyclonal, Dako, Glostrup, Denmark), CD5 (SP19, Ventana Medical Systems), CD4 (SP35, Ventana), CD8 (SP57, Ventana), CD10 (SP67, Ventana), CD20 (L26, Ventana), CD79a (MRQ-48, Ventana), CD30 (Ber-H2, Dako) and MUM1 (MUM1P, Dako). The EBV antigens were visualized using antibodies to LMP (LMP clones CS.1-4, Dako) and EBNA2 (PE2; Abcam, Cambridge, UK). EBV-RNA (EBER) expression was identified by in-situ hybridization (ISH iView Blue Detection kit; Ventana). In each case, EBV status in the PTLD cell population was evaluated by the authors (S.H.D. and M.V.) and recorded as either positive or negative.

Vase M.Ø., Maksten E.F., Strandhave C., Søndergaard E., Bendix K., Hamilton-Dutoit S., Andersen C., Møller M.B., Sørensen S.S., Kampmann J., Eiskjær H., Iversen M., Weinreich I.D., Møller B., Jespersen B, & d'Amore F. (2015). HLA Associations and Risk of Posttransplant Lymphoproliferative Disorder in a Danish Population-Based Cohort. Transplantation Direct, 1(7), e25.

+ Open protocol

+ Expand

Establishing a Danish PTCL Cohort

Check if the same lab product or an alternative is used in the 5 most similar protocols

The establishment of a Danish cohort of 169 patients diagnosed with PTCL between 1984-2011 has been previously described 5 . Formalin-fixed, paraffin-embedded tissue specimens were retrieved from pre-therapeutic biopsies of previously untreated, newly diagnosed patients, aged 16 years or older, where pre-and post therapeutic clinical information were available. Two expert haematopathologists reviewed and reclassified the cases in accordance with the 2008 WHO classification 9 . Clinicopathological data were obtained from the population-based database of the Danish lymphoma registry 19 and supplemented by medical records. Tissue microarrays (TMA) were constructed using a TMA master-01 (3DHISTECH Ltd., Budapest, Hungary) using four cores per case. Six cases (4%) were excluded due to inadequate material.
The study was approved by The Central Denmark Region Committees on Health Research Ethics (record no. 1-10-72-392-12) and the Danish Data Protection Agency (record no. 1-16-02-26-11). The project was conducted in accordance with the Helsinki Declaration.

Holst J.M., Ludvigsen M., Hamilton-Dutoit S.J., Bendix K., Plesner T.L., Nørgaard P., Møller M.B., Steiniche T., Rabinovich G.A., d'Amore F, & Pedersen M.B. (2020). High intratumoural galectin-1 expression predicts adverse outcome in ALK^- ALCL and CD30⁺ PTCL-NOS. Hematological oncology, 38(1).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!